Drugs like venetoclax, which focuses on intrinsic apoptotic pathways, are already in use, and BH3-mimetics that directly provoke apoptosis by inhibiting pro-survival BCL-2 proteins are now in clinical testing as cancer therapies. The gene discussed is BCL2; the disease is cancer.